- October 9, 2019 at 11:29 am #24779
Salbutamol (also known as albuterol) is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of respiratory conditions like asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart.
Salbutamol is indicated for the relief of:
Bronchospasm in asthma
Any other cause of bronchospasm, such as:
Shortness of breath with expiratory wheeze
Salbutamol is contraindicated in cases of:
Premature membrane rupture with chorioamnionitis
Increase in heart rate- this is dose-dependent, but is rarely a major problem.
Hypotension may occur.
By affecting pulmonary mismatch, can cause increased hypoxia and hence, pulse oximetry and supplemental oxygen should be used.
Fine tremor is seen in about 20% of patients.
Less common reactions are such as nausea, vomiting, and dizziness
Most common side effects-fine tremor, anxiety, headache, muscle cramps, dry mouth, and palpitation.
Drug interactions-Special warnings/precautions for use
Bronchodilators should not be the only or primary treatment for severe or unstable asthma.
Increasing bronchodilator use, especially short-acting inhaled beta2-agonists to relieve symptoms indicates deterioration of asthma control. If patients find that short-acting relief bronchodilator treatment becomes less effective or they need more inhalations than usual, immediate medical intervention is recommended.
Salbutamol causes peripheral vasodilation which may result in reflex tachycardia and increased cardiac output
Hyperthyroidism- Salbutamol should only be administered cautiously to patients suffering from thyrotoxicosis after careful evaluation of the benefits and risks of treatment.
Constant monitoring of potassium levels in patients with severe asthma is essential; potentially serious hypokalaemia may result from beta-2 agonist therapy.https://wcts.app/huNxBR
- October 10, 2019 at 10:15 am #24830
You must be logged in to reply to this topic.